ID

39111

Beschrijving

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01155063

Link

https://clinicaltrials.gov/show/NCT01155063

Trefwoorden

Versies (1)
  1. 01-12-19 01-12-19 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

1 december 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Early Breast Cancer NCT01155063

Engels

Eligibility Early Breast Cancer NCT01155063

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
postmenopausal females.
Beschrijving

Postmenopausal state

Datatype

boolean

Alias
UMLS CUI [1]
C0232970
patients who have had surgical treatment for histological confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
Beschrijving

Operative Surgical Procedure Breast Carcinoma | Neoplasm Metastasis Absent

Datatype

boolean

Alias
UMLS CUI [1,1]
C0543467
UMLS CUI [1,2]
C0678222
UMLS CUI [2,1]
C0027627
UMLS CUI [2,2]
C0332197
patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.
Beschrijving

Disease Free | Status post Adjuvant therapy | Tamoxifen

Datatype

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0332296
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C0677850
UMLS CUI [3]
C0039286
patients whose tumour was estrogen receptor positive (er+).
Beschrijving

Estrogen receptor positive tumor

Datatype

boolean

Alias
UMLS CUI [1]
C1562312
evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Beschrijving

Informed Consent | Informed Consent Patient Representative

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C0030701
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients for whom aromasin® treatment is contraindicated (see spc).
Beschrijving

Medical contraindication Aromasin

Datatype

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0876723
presence of metastasis or a contra lateral tumour.
Beschrijving

Neoplasm Metastasis | Tumor Contralateral

Datatype

boolean

Alias
UMLS CUI [1]
C0027627
UMLS CUI [2,1]
C0027651
UMLS CUI [2,2]
C0441988
other adjuvant endocrine therapy.
Beschrijving

Hormone Therapy Adjuvant

Datatype

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C1522673
another concomitant antineoplastic treatment.
Beschrijving

Cancer treatment Other

Datatype

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205394
participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
Beschrijving

Study Subject Participation Status | Investigational New Drugs

Datatype

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
Terug naar het begin van de pagina

Similar models

Eligibility Early Breast Cancer NCT01155063

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state
Item
postmenopausal females.
boolean
C0232970 (UMLS CUI [1])
Operative Surgical Procedure Breast Carcinoma | Neoplasm Metastasis Absent
Item
patients who have had surgical treatment for histological confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.
boolean
C0543467 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Disease Free | Status post Adjuvant therapy | Tamoxifen
Item
patients who are disease-free after 2 or 3 years of adjuvant tamoxifen treatment.
boolean
C0012634 (UMLS CUI [1,1])
C0332296 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0677850 (UMLS CUI [2,2])
C0039286 (UMLS CUI [3])
Estrogen receptor positive tumor
Item
patients whose tumour was estrogen receptor positive (er+).
boolean
C1562312 (UMLS CUI [1])
Informed Consent | Informed Consent Patient Representative
Item
evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Aromasin
Item
patients for whom aromasin® treatment is contraindicated (see spc).
boolean
C1301624 (UMLS CUI [1,1])
C0876723 (UMLS CUI [1,2])
Neoplasm Metastasis | Tumor Contralateral
Item
presence of metastasis or a contra lateral tumour.
boolean
C0027627 (UMLS CUI [1])
C0027651 (UMLS CUI [2,1])
C0441988 (UMLS CUI [2,2])
Hormone Therapy Adjuvant
Item
other adjuvant endocrine therapy.
boolean
C0279025 (UMLS CUI [1,1])
C1522673 (UMLS CUI [1,2])
Cancer treatment Other
Item
another concomitant antineoplastic treatment.
boolean
C0920425 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Study Subject Participation Status | Investigational New Drugs
Item
participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial